Cyclerion Therapeutics Inc (NAS:CYCN)
$ 2.7 0.41 (17.98%) Market Cap: 6.75 Mil Enterprise Value: 1.05 Mil PE Ratio: 0 PB Ratio: 0.68 GF Score: 47/100

Cyclerion Therapeutics Inc Call to Discuss CY6463 MELAS Clinical Data Transcript

Jun 28, 2022 / 12:00PM GMT
Release Date Price: $11.43 (-5.55%)
Philip Yeske

Hello, everyone, and welcome to this special webinar hosted by the United Mitochondrial Disease Foundation entitled Clinical Data Update from study of CY6463 and MELAS. We're really excited to be with you today and do this webinar in partnership with Cyclerion. If I can have the next slide, please. Because some of you perhaps are not familiar with UMDF. I thought we'd take just a minute to introduce the foundation.

We are a 26 year-old foundation based in the United States, national in scope, but global in reach. We have 4 main components of our mission. Research, education, support and advocacy. I represent the research side of the of the foundation. And today, we're going to talk about some specific aspects of that.

And on the next slide, for the patients that have joined us today, I'd like to just remind you of a couple of really important initiatives that fit perfectly within today's webinar. First of all, we have a very active clinical research taking place right now in mitochondrial disease.

And our clinical trial finder on the website is a perfect place for you to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot